In a randomized phase III trial of induction therapy in adult acute myeloid leukaemia, the addition of cladribine, but not fludarabine, to daunorubicin and cytarabine seemed to improve complete response rates and overall survival. However, serious methodological problems make it difficult to estimate the actual clinical importance of the result.
Key Points
-
Patients who receive standard induction chemotherapy for adult acute myeloid leukaemia should have a bone marrow biopsy performed 7–10 days after completion of chemotherapy to document hypoplasia
-
If residual leukaemia is present, additional treatment is recommended
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Appelbaum, F. R. in Clinical Oncology 4th edn Ch. 104 (eds Abeloff, M. D. et al.) 2215–2234 (Elsevier, Philadelphia, USA, 2008).
Burnett, A. K. et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. 29, 369–377 (2011).
Holowiecki, J. et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2011.37.1286.
Holowiecki, J. et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18, 989–997 (2004).
Fernandez, H. F. et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361, 1249–1259 (2009).
Petersdorf, S. et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. Blood 114, a790 (2009).
Ohtake, S. et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood 117, 2358–2365 (2011).
O'Donnell, M. R. et al. Acute myeloid leukemia. J. Natl Compr. Canc. Netw. 9, 280–317 (2011).
Luger, S. M. Is a nadir bone marrow required and, if so, what to do with residual disease? Best Pract. Res. Clin. Haematol. 24, 527–532 (2011).
Gandhi, V. et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmocodynamic, and molecular interactions. Blood 87, 256–264 (1996).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Appelbaum, F. The rule of three in AML induction—is cladribine the answer?. Nat Rev Clin Oncol 9, 376–377 (2012). https://doi.org/10.1038/nrclinonc.2012.98
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.98